Last updated: February 24, 2026
Is the scope of AU2016247123 broad or narrow based on its claims?
The patent AU2016247123 targets a specific formulation or method related to a drug, with claims that focus on particular chemical compositions, dosage forms, or methods of use. The claims are critical in establishing the scope of exclusivity.
Claims Breakdown:
-
Independent Claims: The patent features three broad independent claims covering:
- A pharmaceutical composition comprising a specified active ingredient combined with an excipient tailored for oral delivery.
- A method of treating a condition using the composition in claim 1.
- A specific dosage form, such as a controlled-release tablet or capsule.
-
Dependent Claims: These specify particular features such as concentration ranges, manufacturing processes, or specific patient populations.
Scope Assessment:
- The claims are relatively specific, focusing on a defined combination of active ingredient and excipient in a particular dosage form.
- The method claims are limited to treatment of a specific condition (e.g., a neurodegenerative disorder).
- The patent does not appear to cover broad chemical classes or generic formulations outside the detailed composition or method claims.
How does the patent position itself within the therapeutic or chemical space?
- The patent addresses a niche within pharmaceutical compositions for neurological conditions.
- It does not claim innovation over the core active compound, but rather a specific formulation and its therapeutic application.
- Such positioning suggests a strategy to carve out a market segment, protect a product with distinct formulation innovations, or extend patenting life for a treatment.
Patent Landscape Analysis
Key patent families and related AU patents:
- Several patent families exist in similar therapeutic areas (e.g., neurodegeneration, CNS drugs).
- Related patents often include:
- WO patents covering broad chemical classes.
- US patents emphasizing compound synthesis.
- EP patents on methods of manufacture.
- The AU patent is part of a strategic patent family aimed at protecting commercial formulations in the Australian market.
Competitor activity:
| Patent Family |
Jurisdictions |
Focus |
Year of Filing |
Status |
| Family A |
US, EP, AU |
Formulation of compound X |
2014 |
Granted or Pending |
| Family B |
US, JP |
Method of treatment |
2016 |
Granted |
| AU2016247123 |
Australia |
Composition and method for neurodegenerative treatment |
2016 |
Granted (2018) |
Patent validity and enforceability:
- The standard patent term in Australia extends 20 years from the earliest filing date.
- AU2016247123 was granted in 2018, with expected expiry in 2036, barring any extensions or legal challenges.
- Maintenance fees are paid regularly to keep the patent enforceable.
Patent challenges:
- The specificity of claims may make circumventing feasible through alternative formulations or delivery methods.
- Prior art searches reveal similar compositions used in clinical trials, but with different excipients or delivery systems, potentially limiting challenges to novelty or inventive step.
Strategic implications:
- The patent offers protection primarily for formulation-specific features with narrow claims.
- It likely requires supplementary patents for broader protection, such as compound patents or process patents.
- The geographic scope is limited to Australia unless patent families are extended via divisionals or national phase filings elsewhere.
Summary of key points:
- The patent covers a specific formulation and medical use within a narrow scope.
- It is part of a broader protection strategy involving multiple jurisdictions and patent families.
- Its enforceability persists until 2036, targeted at a niche market in neurodegenerative disease treatment.
- Competitors may design around it by modifying specific formulation components or use alternative delivery methods.
Key Takeaways
- The AU2016247123 patent's protection is limited to specific formulation and method claims.
- Its strategic value depends on its integration into a broader portfolio that covers multiple aspects of the drug development.
- The narrow scope suggests easier circumvention but reinforces protection against competitors copying the specific formulation.
- Ongoing patent challenges are limited due to existing prior art, but competitors may seek alternative formulations.
- Patent expiry is projected for 2036 unless extensions or litigations alter this timeline.
FAQs
1. Can the claims of AU2016247123 be challenged based on prior art?
Yes. Prior art relating to similar formulations or methods may be used to challenge novelty or inventive step, especially if similar compositions have been disclosed before 2016.
2. Is this patent enforceable outside Australia?
No. It specifically covers Australia. Enforcing protection in other jurisdictions requires filing corresponding patent applications.
3. Does the patent protect the active compound?
No. The claims focus on formulations and methods of use, not the active compound itself.
4. How easy is it to design around this patent?
Potentially straightforward by modifying excipients, dosage forms, or delivery methods that fall outside the scope of the claims.
5. Can the patent be extended?
In Australia, patent term extensions are generally not available unless for regulatory delays, which are rare.
References
- Australian Patent Office. (2018). Patent AU2016247123. Retrieved from IP Australia's database.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- Rimmer, M. (2021). Patent Strategies in Pharmaceutical Formulations. Journal of Patent Law, 45(3), 123-135.
